{
    "id": "60386923",
    "text": "Sotagliflozin (INN; trade name Zynquista) is a drug approved in European Union for people with type 1 diabetes.Zynquista approved in EU for certain patients with type I diabetes The Food and Drug Administration refused its approval for use in combination with insulin for the treatment of type 1 diabetes. It is developed by Sanofi. Sotagliflozin is a sodium/glucose cotransporter 2 (SGLT2) inhibitor and is in the class of drugs known as gliflozins. ==References== == External links == * Category:SGLT2 inhibitors Category:Diabetes-related supplies and medical equipment ",
    "title": "Sotagliflozin"
}